var data={"title":"Ropivacaine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ropivacaine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6924?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ropivacaine-drug-information\" class=\"drug drug_general\">see &quot;Ropivacaine: Drug information&quot;</a> and <a href=\"topic.htm?path=ropivacaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ropivacaine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219215\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Naropin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219216\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Naropin;</li>\n      <li>Ropivacaine Hydrochloride Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061901\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Local Anesthetic, Injectable</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50683504\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note</b>: Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient; should only be administered under the supervision of a qualified physician experienced in the use of anesthetics. Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010). Dosing units variable (mL/kg, <b>mg/kg</b>); use extra precaution to ensure accuracy and minimize potential toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central nerve blocks/anesthesia (eg, caudal, lumbar, thoracic):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Caudal block:</i> Term neonate: Caudal injection: 0.2% (2 mg/mL) solution: 1 mL/kg (Ivani 2008; Wulf 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Epidural block (eg, lumbar, thoracic):</i> Term neonate: Epidural injection: 0.2% (2 mg/mL) solution: Reported range: 0.5 to 1 mL/kg; if repeat injections necessary, a decreased dose is necessary to prevent drug accumulation. Some experts suggest if at least 45 minutes since initial dose, reduce dose to <sup>1</sup>/<sub>3</sub> of the initial or if at least 90 minutes since initial dose, then reduce dose to half of the initial. If additional doses are necessary, doses should be reduced to half of the previous dose (Bosenberg 2005; Ivani 2008; Miller 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Epidural, continuous infusion:</i> Term neonate: Epidural injection: Bolus: Usual concentration: 0.2% (2 mg/mL) solution: Usual range: 0.5 to 1 mL/kg, bolus dose volume dependent upon site (eg, thoracic [lower dose range] or lumbar); reported range: 0.45 to 1 mL/kg. In some cases, a more dilute solution (eg, 0.1% [1 mg/mL]) may be required to ensure adequate volume and minimize toxicity. Follow with continuous epidural infusion of 0.2% (2 mg/mL) solution at 0.2 <b>mg/kg</b>/hour (Bosenberg 2005; Ivani 2008; J&ouml;hr 2015; Miller 2015; Walker 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061894\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ropivacaine-drug-information\" class=\"drug drug_general\">see &quot;Ropivacaine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note</b>: Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010). Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: Dosing units variable (mL/kg, <b>mg/kg</b>); use extra precaution to ensure accuracy and minimize potential toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Central nerve blocks/anesthesia (eg, caudal, lumbar, thoracic): </b>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Caudal block:</i> Infants and Children: Caudal injection: 0.2% (2 mg/mL) solution: 0.5 to 1 mL/kg; some experts suggest a maximum volume of 25 mL (Ivani 1998; Ivani 2002; J&ouml;hr 2015; Kokinsky 2003; Lonnqvist 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Epidural block</i> <i>(eg, lumbar, thoracic):</i> Infants, Children, and Adolescents: Epidural injection 0.2% (2 mg/mL): 0.7 mL/kg<b>. Note</b>: For infants (particularly young infants) if repeat injections necessary, a decreased dose may be necessary to prevent drug accumulation. Some experts suggest if at least 45 minutes since initial dose, reduce dose to <sup>1</sup>/<sub>3</sub> of the initial or if at least 90 minutes since initial dose, then reduce dose to half of the initial. If additional doses are necessary, doses should be reduced to half of the previous dose (Ivani 1999; Miller 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Epidural, continuous infusion</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &lt;3 months: Epidural injection: Bolus: Usual concentration 0.2% (2 mg/mL) solution: Reported range: 0.5 to 1 mL/kg. In some cases, a more dilute solution (eg, 0.1% [1 mg/mL]) may be required to ensure adequate volume and minimize toxicity. Follow with continuous epidural infusion of 0.2% (2 mg/mL) solution at 0.2 <b>mg/kg</b>/hour (Bosenberg 2005; Hansen 2000; Miller 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;3 months, Children, and Adolescents: Epidural injection: 0.2% (2 mg/mL) solution: Bolus: Reported range: 0.5 to 1 mL/kg administered over several minutes (eg, 3 to 5 minutes) followed by continuous epidural infusion at 0.4 <b>mg/kg</b>/hour; in adults, usual rates are 6 to 14 mL/hour of 0.2% solution (Berde 2008; Bosenberg 2005; Hansen 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peripheral nerve blocks/ local anesthesia: </b>Limited data available: <b>Note:</b> Dose varies with location of block (ie, procedure), depth of anesthesia, vascularity of tissues, duration of anesthesia, and patient parameters (eg, age, weight, condition).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Single injection:</i> The volume of dose (mL/kg) and concentration of solution are site-specific based upon anatomy and variable among patients and procedure (Cot&eacute; 2013; Miller 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;6 months, Children, and Adolescents: Suggested or reported dose volumes presented; not to exceed a suggested maximum dose of 3 <b>mg/kg</b>/dose based on lean body mass; dosing based on extrapolation from adult experience; additional data necessary to more clearly define pediatric upper dose limit. <b>Note:</b> For infants &lt;6 months, dose reductions (eg, by 30%) have been suggested by experts (Cot&eacute; 2013; Visoiu 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Head and neck blocks: 0.05 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maxillary nerve: 0.15 mL/kg (Chiono 2014; Sola 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Upper extremity blocks:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Brachial plexus: 0.2 to 0.3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Digital nerve: &le;0.2% (2 mg/mL) solution: 0.05 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Trunchal blocks:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Transversus abdominis plane: 0.2 to 0.5 mL/kg (J&ouml;hr 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Ilioinguinal nerve: 0.075 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Rectus sheath: 0.1 to 0.2 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lower extremity blocks:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Femoral nerve: 0.2% to 0.5% (2 to 5 mg/mL) solution: 0.2 to 0.4 mL/kg (Cot&eacute; 2013; Schloss 2014; Veneziano 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Sciatic nerve: 0.2 to 0.3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous peripheral nerve block infusion (CPNB) (Dadure 2009; Duflo 2006; Iliev 2016; Visoiu 2014): </i>Infants &ge;6 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial bolus: 0.2% (2 mg/mL) solution: Dose dependent on nerve catheter location: Commonly reported dose range: ~0.5 to 1.32 <b>mg/kg</b>; some patients and/or catheter/nerve sites may require a higher bolus dose; a trial evaluating 403 pediatric catheter placements reported an overall median bolus for all catheter sites of 1.32 mg/kg (IQR: 0.82 to 1.95 mg/kg); another trial reporting on 339 pediatric catheter placements reported a mean initial bolus dose of 0.49 to 0.98 mg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous peripheral nerve block infusion: 0.2% (2 mg/mL) solution: Reported mean rate range: 0.11 to 0.25 <b>mg/kg</b>/hour (most experience reported at 0.2 to 0.25 <b>mg/kg</b>/hour); reported IQR range from 403 pediatric catheter placements: 0.12 to 0.33 <b>mg/kg/</b>hour (depending upon catheter site) with a usual duration &lt;72 hours; majority of experience is postoperative pain management following orthopedic procedures including administration via On-Q pump or Ambu Smart-Infuser</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Spinal anesthesia: </b>Limited data available: Infant, Children, and Adolescents &le;17 years: Intrathecal (via LP site; L 3-5): Preservative-free 0.5% (5 mg/mL) isobaric solution: 0.5 <b>mg/kg</b>; maximum dose: 20 mg/dose (Kokki 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note: </b>Dose varies with procedure, onset and depth of anesthesia desired, vascularity of tissues, duration of anesthesia, and condition of patient: A test dose of short acting local anesthestic containing epinephrine (eg, 3 to 5 mL) should be administered prior to induction of complete block with ropivacaine. Incremental ropivacaine dosing is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lumbar epidural block for surgery:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to 30 <b>mL</b> of 0.5% solution</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to 25 <b>mL</b> of 0.75% solution</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to 20 <b>mL</b> of 1% solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lumbar epidural block for cesarean section:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">20 to 30 <b>mL</b> dose of 0.5% solution</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to 20 <b>mL</b> dose of 0.75% solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Thoracic epidural block:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">5 to 15 <b>mL</b> dose of 0.5% solution</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">5 to 15 <b>mL</b> dose of 0.75% solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Major nerve block:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">35 to 50 <b>mL</b> dose of 0.5% solution</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">10 to 40 <b>mL</b> dose of 0.75% solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Field block: 1 to 40 <b>mL</b> dose of 0.5% solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Labor pain management: Lumbar epidural: Initial: 10 to 20 <b>mL</b> 0.2% solution; continuous infusion dose: 6 to 14 <b>mL</b>/hour of 0.2% solution with incremental injections of 10 to 15 <b>mL</b>/hour of 0.2% solution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peripheral nerve block: Continuous infusion dose: 5 to 10 <b>mL</b>/hour of 0.2% solution (Bagry 2008; Klein 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lumbar or thoracic epidural: Continuous infusion dose: 6 to 14 <b>mL</b>/hour of 0.2% solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infiltration/minor nerve block:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">1 to 100 <b>mL</b> dose of 0.2% solution</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">1 to 40 <b>mL</b> dose of 0.5% solution</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, ropivacaine and its metabolites are renally excreted, and the risk of toxic reactions may be greater.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution; ropivacaine undergoes hepatic metabolism and patients may be at a greater risk for developing toxic drug levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219198\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5% (100 mL); 0.1% in NaCl 0.9% (200 mL); 0.15% in NaCl 0.9% (100 mL); 0.2% in NaCl 0.9% (100 mL, 250 mL, 400 mL, 500 mL); 0.25% in NaCl 0.9% (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (300 mL); 0.1% in NaCl 0.9% (100 mL, 250 mL, 400 mL, 550 mL, 600 mL); 0.2% in NaCl 0.9% (100 mL, 250 mL, 400 mL, 500 mL, 550 mL, 650 mL, 750 mL); 0.25% in NaCl 0.9% (400 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naropin: 2 mg/mL (10 mL, 20 mL, 100 mL, 200 mL); 5 mg/mL (20 mL, 30 mL, 100 mL [DSC], 200 mL); 7.5 mg/mL (20 mL); 10 mg/mL (10 mL, 20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (10 mL, 20 mL, 100 mL); 5 mg/mL (20 mL, 30 mL); 7.5 mg/mL (20 mL); 10 mg/mL (10 mL, 20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.2% in NaCl 0.9% (10 mL, 60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219185\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061904\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral:Administered via local infiltration, epidural block and epidural infusion, or intermittent bolus; if further dilution necessary, ensure appropriate diluent (eg, preservative-free). Prior to ropivacaine administration, a test dose of short acting local anesthestic with epinephrine should be administered to verify avoidance of intravascular site. Incremental ropivacaine dosing is recommended. Do not administer large volume of anesthetic rapidly. The On-Q infusion pump is used to slowly administer local anesthetics (eg, bupivacaine, lidocaine, ropivacaine) to or around surgical wound sites and/or in close proximity to nerves for pre- or postoperative regional anesthesia. When infused directly into the shoulder, destruction of articular cartilage (chondrolysis) has occurred. On-Q pumps should never be placed directly into any joint (see https://www.ismp.org/Newsletters/acutecare/archives/May09.asp).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219212\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Infusions should be discarded after 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061903\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Production of local or regional anesthesia for surgery administered as an epidural block, including cesarean section, major nerve block, or local infiltration; acute pain management administered as an epidural continuous infusion, intermittent bolus (eg, postoperative or labor), or local infiltration (All indications: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219253\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ropivacaine may be confused with bupivacaine, rOPINIRole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Infusion bottles of Naropin (ropivacaine) and Ofirmev (acetaminophen) look similar. Potentially fatal mix-ups have been reported in which a glass bottle of Naropin was mistaken for Ofirmev in perioperative areas.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219251\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, chest pain, hypertension, hypotension (dose-related and age-related), tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, chills, dizziness, headache, hypoesthesia, paresthesia, rigors, shivering</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, oral paresthesia, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Oliguria, urinary retention, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema, apnea (usually associated with epidural block in head/neck region), bronchospasm, cardiac insufficiency, chondrolysis (continuous intra-articular administration), circulatory shock, dyskinesia, hallucination, hypersensitivity reaction, hyperthermia, laryngeal edema, myocardial infarction, seizure, skin rash, syncope, tinnitus, urticaria, ventricular arrhythmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219203\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ropivacaine, amide-type local anesthetics (eg, bupivacaine, mepivacaine, lidocaine), or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Intravenous regional anesthesia (Bier block); obstetric paracervical block anesthesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219189\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with hypotension, hypovolemia, heart block, or cardiovascular disease; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurological disorders: Use with caution in patients with neurological disorders; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Porphyria: Use with caution in patients with acute porphyria; consider use of alternative agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psychiatric disorders: Use with caution in patients with psychiatric disorders; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acutely ill patients: Use with caution in acutely ill;  may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Debilitated patients: Use with caution in debilitated patient; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly: may be at greater risk for toxicity. Cardiovascular adverse events (bradycardia, hypotension) may be age-related (more common in patients &gt;61 years of age).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rapid administration: Ropivacaine is not recommended for use in emergency situations where rapid administration is necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219240\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219194\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12775&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of Bupivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine, but the optimal duration of dose separation for other local anesthetics is unknown<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Ropivacaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of Ropivacaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propofol: May increase the serum concentration of Ropivacaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219196\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219205\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. When used for epidural block during labor and delivery, systemically absorbed ropivacaine may cross the placenta, resulting in varying degrees of fetal or neonatal effects (eg, CNS or cardiovascular depression). Fetal or neonatal adverse events include fetal bradycardia (12%), neonatal jaundice (8%), low Apgar scores (3%), fetal distress (2%), neonatal respiratory disorder (3%). Maternal hypotension may also result from systemic absorption. In cases of hypotension, position pregnant woman in left lateral decubitus position to prevent aortocaval compression by the gravid uterus. Epidural anesthesia may prolong the second stage of labor. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061900\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">After epidural or subarachnoid administration: Blood pressure, heart rate, respiration, signs of CNS toxicity (lightheadedness, dizziness, tinnitus, restlessness, tremors, twitching, drowsiness, circumoral paresthesia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219188\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219202\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Anesthesia (route dependent): 3 to 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (dose and route dependent): 3 to 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children: Epidural infusion: 2.1 to 4.2 L/kg (Hansen 2000)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: Intravascular infusion: 41 &plusmn; 7 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, via CYP1A2 to metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Epidural: Terminal phase: 4.9 hours (range: 3 to 6.7 hours) (Hansen 2000) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Epidural: 5 to 7 hours; IV: Terminal: 111 &plusmn; 62 minutes (Lee, 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Dose and route dependent: Caudal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: Median: 60 minutes (range: 15 to 90 minutes) (Wulf 2000) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Mean: 60 minutes (range: 12 to 249 minutes (Lonnqvist 2000) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (86% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323799\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Naropin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (100 mL): $46.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (30 mL): $26.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg/mL (20 mL): $22.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $27.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ropivacaine HCl (PF) Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (100 mL): $84.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ropivacaine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (10 mL): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (30 mL): $24.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg/mL (20 mL): $7.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $8.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ropivacaine HCl-NaCl (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1-0.9% (400 mL): $77.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2-0.9% (550 mL): $222.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25-0.9% (400 mL): $176.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ropivacaine HCl-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1-0.9% (200 mL): $40.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15-0.9% (100 mL): $36.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2-0.9% (400 mL): $140.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25-0.9% (150 mL): $66.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Ropivacaine HCl-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2-0.9% (10 mL): $8.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219206\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anaropin (VN);</li>\n      <li>Narop (IL, SE);</li>\n      <li>Naropeine (FR, GR, PT, VN);</li>\n      <li>Naropin (AE, AR, AT, AU, BB, BE, BH, BM, BS, BZ, CH, CN, CO, CR, CY, CZ, DE, DK, DO, EG, ES, FI, GB, GT, GY, HK, HN, ID, IE, IQ, IR, IS, JM, JO, KR, KW, LB, LU, LY, MX, MY, NI, NL, NZ, OM, PA, PH, PL, QA, RO, RU, SA, SG, SI, SR, SV, SY, TH, TR, TT, UA, VE, YE);</li>\n      <li>Naropina (IT);</li>\n      <li>Ropibam (AU);</li>\n      <li>Ropica (TW);</li>\n      <li>Ropiva (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bagry H, de la Cuadra Fontaine JC, Asenjo JF, Bracco D, Carli F. Effect of a continuous peripheral nerve block on the inflammatory response in knee arthroplasty. <i>Reg Anesth Pain Med</i>. 2008;33(1):17-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/18155052/pubmed\" target=\"_blank\" id=\"18155052\">18155052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde CB, Yaster M, Meretoja O, et al. Stable plasma concentrations of unbound ropivacaine during postoperative epidural infusion for 24-72 hours in children. <i>Eur J Anaesthesiol</i>. 2008;25(5):410-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/18205962/pubmed\" target=\"_blank\" id=\"18205962\">18205962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    B&ouml;senberg AT, Thomas J, Cronje L, et al. Pharmacokinetics and efficacy of ropivacaine for continuous epidural infusion in neonates and infants. <i>Paediatr Anaesth</i>. 2005;15(9):739-749.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/16101704/pubmed\" target=\"_blank\" id=\"16101704\">16101704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chiono J, Raux O, Bringuier S, et al. Bilateral suprazygomatic maxillary nerve block for cleft palate repair in children: a prospective, randomized, double-blind study versus placebo. <i>Anesthesiology</i>. 2014;120(6):1362-1369.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/24525630/pubmed\" target=\"_blank\" id=\"24525630\">24525630</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cot&eacute; CJ, ed. <i>A Practice of Anesthesia for Infants and Children</i>. 5th ed.Philadelphia, PA: Elsevier Inc; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dadure C, Bringuier S, Raux O, et al. Continuous peripheral nerve blocks for postoperative analgesia in children: feasibility and side effects in a cohort study of 339 catheters. <i>Can J Anaesth</i>. 2009;56(11):843-850.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/19697092/pubmed\" target=\"_blank\" id=\"19697092\">19697092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dadure C, Capdevila X. Peripheral catheter techniques. <i>Paediatr Anaesth</i>. 2012;22(1):93-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/22050550/pubmed\" target=\"_blank\" id=\"22050550\">22050550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duflo F, Sautou-Miranda V, Pouyau A, et al. Efficacy and plasma levels of ropivacaine for children: controlled regional analgesia following lower limb surgery. <i>Br J Anaesth</i>. 2006;97(2):250-254.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/16787931/pubmed\" target=\"_blank\" id=\"16787931\">16787931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frawley G, Smith KR, Ingelmo P. Relative potencies of bupivacaine, levobupivacaine, and ropivacaine for neonatal spinal anaesthesia. <i>Br J Anaesth</i>. 2009;103(5):731-738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/19767606/pubmed\" target=\"_blank\" id=\"19767606\">19767606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hansen TG, Ilett KF, Lim SI, et al, &ldquo;Pharmacokinetics and Clinical Efficacy of Long-Term Epidural Ropivacaine Infusion in Children,&rdquo; <i>Br J Anaesth</i>, 2000, 85(3):347-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/11103172/pubmed\" target=\"_blank\" id=\"11103172\">11103172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hansen TG, Ilett KF, Reid C, et al, &ldquo;Caudal Ropivacaine in Infants: Population Pharmacokinetics and Plasma Concentrations,&rdquo; <i>Anesthesiology</i>, 2001, 94(4):579-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/11379676 /pubmed\" target=\"_blank\" id=\"11379676 \">11379676 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iliev P, Bhalla T, Tobias JD. A comparison of the hourly output between the Ambu&reg; Smart-Infuser&trade; Pain Pump and the On-Q Pump&reg; with Select-A-Flow&trade; Variable Rate Controller with standard and overfill volumes. <i>Paediatr Anaesth</i>. 2016;26(4):425-428.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/26786058/pubmed\" target=\"_blank\" id=\"26786058\">26786058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivani G, DeNegri P, Conio A, et al. Comparison of racemic bupivacaine, ropivacaine, and levo-bupivacaine for pediatric caudal anesthesia: effects on postoperative analgesia and motor block. <i>Reg Anesth Pain Med</i>. 2002;27(2):157-161.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/ 3605712 /pubmed\" target=\"_blank\" id=\" 3605712 \"> 3605712 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivani G, Lampugnani E, De Negri P, Lonnqvist PA, Broadman L. Ropivacaine vs bupivacaine in major surgery in infants. <i>Can J Anaesth</i>. 1999;46(5 Pt 1):467-469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/10349927/pubmed\" target=\"_blank\" id=\"10349927\">10349927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivani G, Lampugnani E, Torre M, et al. Comparison of ropivacaine with bupivacaine for paediatric caudal block. <i>Br J Anaesth</i>. 1998;81(2):247-248.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/9813532/pubmed\" target=\"_blank\" id=\"9813532\">9813532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivani G, Mossetti V. Regional anesthesia for postoperative pain control in children: focus on continuous central and perineural infusions. <i>Paediatr Drugs</i>. 2008;10(2):107-114.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/18345720/pubmed\" target=\"_blank\" id=\"18345720\">18345720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    J&ouml;hr M. Regional anaesthesia in neonates, infants and children: an educational review. <i>Eur J Anaesthesiol</i>. 2015;32(5):289-297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/25693139/pubmed\" target=\"_blank\" id=\"25693139\">25693139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein SM, Grant SA, Greengrass RA, et al. Interscalene brachial plexus block with a continuous catheter insertion system and a disposable infusion pump. <i>Anesth Analg</i>. 2000;91(6):1473-1478.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/11094003/pubmed\" target=\"_blank\" id=\"11094003\">11094003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kokinsky E, Nilsson K, Larsson LE. Increased incidence of postoperative nausea and vomiting without additional analgesic effects when a low dose of intravenous fentanyl is combined with a caudal block. <i>Paediatr Anaesth</i>. 2003;13(4):334-338.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/12753447/pubmed\" target=\"_blank\" id=\"12753447\">12753447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kokki H, Yl&ouml;nen P, Laisalmi M, Heikkinen M, Reinikainen M. Isobaric ropivacaine 5 mg/ml for spinal anesthesia in children. <i>Anesth Analg</i>. 2005;100(1):66-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/15616053/pubmed\" target=\"_blank\" id=\"15616053\">15616053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee A, Fagan D, Lamont M, Tucker GT, Halldin M, Scott DB. Disposition kinetics of ropivacaine in humans. <i>Anesth Analg</i>. 1989;69(6):736-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/2589653/pubmed\" target=\"_blank\" id=\"2589653\">2589653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lonnqvist PA, Westrin P, Larsson BA, et al, &ldquo;Ropivacaine Pharmacokinetics After Caudal Block in 1-8 Year Old Children,&rdquo; <i>Br J Anaesth</i>, 2000, 85(4):506-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/11064606 /pubmed\" target=\"_blank\" id=\"11064606 \">11064606 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, ed. <i>Miller's Anesthesia</i>. 8th ed. Philadelphia, PA: Elsevier, Inc; 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/1340763/pubmed\" target=\"_blank\" id=\"1340763\">1340763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. <i>Reg Anesth Pain Med</i>. 2010;35(2):177-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/20216035/pubmed\" target=\"_blank\" id=\"20216035\">20216035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naropin (ropivacaine) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA, LLC; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schloss B, Bhalla T, Klingele K, Phillips D, Prestwich B, Tobias JD. A retrospective review of femoral nerve block for postoperative analgesia after knee surgery in the pediatric population. <i>J Pediatr Orthop</i>. 2014 ;34(4):459-461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/24172670/pubmed\" target=\"_blank\" id=\"24172670\">24172670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sola C, Raux O, Savath L, Macq C, Capdevila X, Dadure C. Ultrasound guidance characteristics and efficiency of suprazygomatic maxillary nerve blocks in infants: a descriptive prospective study. <i>Paediatr Anaesth</i>. 2012;22(9):841-846.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/22587691/pubmed\" target=\"_blank\" id=\"22587691\">22587691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veneziano G, Tripi J, Tumin D, et al. Femoral nerve blockade using various concentrations of local anesthetic for knee arthroscopy in the pediatric population. <i>J Pain Res</i>. 2016;9:1073-1079.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/27920573/pubmed\" target=\"_blank\" id=\"27920573\">27920573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visoiu M. Paediatric regional anaesthesia: a current perspective. <i>Curr Opin Anaesthesiol</i>. 2015;28(5):577-582.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/26308515/pubmed\" target=\"_blank\" id=\"26308515\">26308515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker SM, Yaksh TL. Neuraxial analgesia in neonates and infants: a review of clinical and preclinical strategies for the development of safety and efficacy data. <i>Anesth Analg</i>. 2012;115(3):638-662.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/22798528/pubmed\" target=\"_blank\" id=\"22798528\">22798528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wulf H, Peters C, and Behnke H, &ldquo;The Pharmacokinetics of Caudal Ropivacaine 0.2% in Children. A Study of Infants Aged Less Than 1 Year and Toddlers Aged 1-5 Years Undergoing Inguinal Hernia Repair,&rdquo; <i>Anaesthesia</i>, 2000, 55(8):757-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/10947688/pubmed\" target=\"_blank\" id=\"10947688\">10947688</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12775 Version 121.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F219215\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F219216\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061901\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F50683504\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061894\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F219198\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F219185\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061904\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F219212\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061903\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F219253\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F219251\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F219203\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F219189\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F219240\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F219194\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F219196\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F219205\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061900\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F219188\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F219202\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323799\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F219206\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12775|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ropivacaine-drug-information\" class=\"drug drug_general\">Ropivacaine: Drug information</a></li><li><a href=\"topic.htm?path=ropivacaine-patient-drug-information\" class=\"drug drug_patient\">Ropivacaine: Patient drug information</a></li></ul></div></div>","javascript":null}